BI 6727

volasertib · Boehringer Ingelheim

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for BI 6727, covering 2018-08-06 to 2023-10-03. Get the full timeline:

Most recent: Clinical Trial Update: BI 6727 Administered Intravenously Every 3 Weeks in Patients With Solid Tumours [Phase 1]